dc.contributor.author | Glendenning, Charles | eng |
dc.contributor.author | Kaufmann, Lee | eng |
dc.date.issued | 2007 | eng |
dc.description.abstract | There is no clearly superior oral agent for glycemic control in patients with type 2 diabetes. (Strength of Recommendation [SOR]: C) Metformin (Glucophage) has shown additional benefit when compared with other treatments (including insulin) for diabetes-related outcomes and all-cause mortality and should be considered the agent of choice for initial monotherapy, particularly in obese patients. (SOR: A) | eng |
dc.identifier.uri | http://hdl.handle.net/10355/3983 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2007 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | American family physician, 75, no. 07 (April 2007) | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject | A1C reduction | eng |
dc.subject | alpha-glucosidase inhibitors | eng |
dc.subject | hypoglycemia | eng |
dc.subject | insulin resistance | eng |
dc.subject.lcsh | Non-insulin-dependent diabetes -- Treatment | eng |
dc.subject.lcsh | Hyperglycemia -- Treatment | eng |
dc.subject.lcsh | Blood sugar monitoring | eng |
dc.title | Glycemic Control in Patients with Type 2 Diabetes | eng |
dc.type | Article | eng |